Kameel Farag

Kameel Farag is recorded as CFO at Akari Therapeutics Plc (AKTX) and Board Member at Biovie Inc. (BIVI) since January 1, 2025. The newest filing on record that lists Kameel Farag as CFO at Akari Therapeutics Plc (AKTX) is dated June 4, 2026. The newest filing on record that lists Kameel Farag as Board Member at Biovie Inc. (BIVI) is dated September 28, 2026. Akari Therapeutics Plc reported in an 8-K filed October 23, 2025 that Kameel Farag was appointed interim Chief Financial Officer, effective October 22, 2025. The proxy statement of Akari Therapeutics Plc reports total compensation of $117,435 for Kameel Farag in fiscal 2025, including a base salary of $43,826. Disclosed compensation is on record for 2 fiscal years. Akari Therapeutics Plc is classified in the Biotechnology industry within the Healthcare sector. Biovie Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Akari Therapeutics Plc includes Abizer Gaslightwala (CEO and Board Member), Samir R. Patel (CEO), Samir R. Patel, M.D. (CEO) and 6 others.